Latest Oncology News

Digital Health and Process Improvements   Enhance Community-Based Patient Care

Digital Health and Process Improvements Enhance Community-Based Patient Care

October 20th 2021

Lalan Wilfong, MD

A marked reduction in hospitalizations and emergency department visits are key metrics for value-based care programs. Quality improvement processes and electronic patient management systems may give practices a way to fully embrace these programs and remain mindful of cost while ensuring that patients receive high-quality care.

Novel Combination Immunotherapy Developed at Hollings Cancer Center to be Offered in Lung-MAP Trial

Novel Combination Immunotherapy Developed at Hollings Cancer Center to be Offered in Lung-MAP Trial

October 20th 2021

A bench-to-bedside-pioneered lung cancer immunotherapy developed at MUSC Hollings Cancer Center is to be included in one of the largest lung cancer clinical trials being offered by the National Cancer Institute.

Implementable Changes Could Improve QOL With Radiation-Related Mucositis in Head and Neck Cancer

Implementable Changes Could Improve QOL With Radiation-Related Mucositis in Head and Neck Cancer

October 20th 2021

Jessica Hergert

Anurag Singh, MD, discussed the potential advantage to treating patients with radiation therapy at specific times of day, how the utilization of prophylactic gabapentin has decreased the need for narcotics in managing oral mucositis in patients with head and neck cancer, and the potential use of single-fraction radiation therapy in oncology.

Study Highlights Racial, Ethnic Disparities in Post-Breast Cancer Surgery Emergency Department Visits

Study Highlights Racial, Ethnic Disparities in Post-Breast Cancer Surgery Emergency Department Visits

October 19th 2021

Courtney Marabella

Non-Hispanic Black women are approximately 40% more like to require a visit to the emergency department after breast cancer surgery, and Hispanic women are 11% more likely compared with non-Hispanic White women, according to results from a population-based study published in Breast Cancer Research and Treatment.

Avasopasem Misses the Mark for Radiotherapy-Induced Severe Oral Mucositis in Head and Neck Cancer

Avasopasem Misses the Mark for Radiotherapy-Induced Severe Oral Mucositis in Head and Neck Cancer

October 19th 2021

Kristi Rosa

The dismutase mimetic avasopasem manganese was not found to significantly reduce the incidence of severe oral mucositis in patients with locally advanced head and neck cancer who were receiving standard-of-care radiotherapy, missing the primary end point of the phase 3 ROMAN trial.

Latest Oncology Videos

All Oncology News

UGN-102 May Provide Alternative to Repetitive Surgery in Low-Grade Intermediate-Risk NMIBC

October 19th 2021

Courtney Marabella

Non-surgical primary chemoablation using mitomycin-containing reverse thermal gel UGN-102 produced significant, durable responses in those with low-grade intermediate-risk non–muscle invasive bladder cancer.

Chemoimmunotherapy Combos, Adjuvant Approaches and Bispecifics Are Among Exciting Advances in Lung Cancer

October 19th 2021

Caroline Seymour

The availability of chemoimmunotherapy combinations and targeted agents for common and rare mutations alike in non–small cell lung cancer has fostered discussions that might have been unthinkable just a decade or so ago.

Bicycle Toxin Conjugates Showcase Early Activity and Tolerability in Urothelial, Ovarian Cancers

October 19th 2021

Kristi Rosa

The bicycle toxin conjugates BT5528 and BT8009 have showcased preliminary signs of antitumor activity and encouraging tolerability when administered to patients with solid tumors such as urothelial cancer and ovarian cancer.

Ontada Launches HOPE Studies, Empowering Oncologists to Leverage Real-World Data and Address Healthcare Disparities

October 19th 2021

Ontada, a McKesson business focused on real-world data and evidence, clinical education and provider technology, announced the launch of Health Outcomes Powered by Evidence Studies.

Sacituzumab Govitecan May Be New Standard of Care in Metastatic TNBC

October 19th 2021

Jackie Collins

Hope S. Rugo, MD, FASCO, provides her insights on the final analysis data from the international phase 3 ASCENT trial.

Trial Launches to Evaluate Novel ADC in Previously Treated HER2+ Breast Cancer

October 19th 2021

Jessica Hergert

The phase 2 ACE-Breast03 trial has been launched to evaluate the efficacy and safety of ARX788, an investigational antibody-drug conjugate, in patients with metastatic HER2-positive breast cancer who have progressed on prior HER2-directed therapies.

Novel Strategies With BTK Inhibitors Seek to Impact Frontline MCL Treatment Landscape

October 18th 2021

Ryan Scott

Brad S. Kahl, MD, discusses personalizing frontline treatment in mantle cell lymphoma, clinical trials further examining BTK inhibitors, and research opportunities with CAR T-cell therapy.

Ilson Delves Into the Development of Checkpoint Inhibition in Gastric/GEJ Cancers

October 18th 2021

OncLive Staff

Dr. Ilson discusses treatment sequencing for patients with gastric and gastroesophageal junction cancer, the integration of immunotherapy into the frontline setting, and key ongoing studies in the field.

Inguinofemoral Radiotherapy Represents Safe Alternative to Lymphadenectomy in Vulvar Cancer With Micrometastases

October 18th 2021

Kristi Rosa

Inguinofemoral radiotherapy could potentially spare patients with vulvar cancer and sentinel node micrometastases from the morbidity of a lymphadenectomy.

FDA Grants Orphan Drug Designation to Bispecific Antibody LAVA-051 for CLL

October 18th 2021

Kristi Rosa

The FDA has granted an orphan drug designation to LAVA-051, a CD1d-targeted Gammabody, for the treatment of patients with chronic lymphocytic leukemia.

Pivotal Trial Results Look to Shake Up HCC Treatment

October 18th 2021

Amit Mahipal, MBBS

Hepatocellular cancer, the most common primary liver malignancy, is the fourth-leading cause of cancer-related deaths globally.

Margaret Gilshannon named Deputy Director for Finance & Administration at Yale Cancer Center

October 18th 2021

Margaret Gilshannon, MHA, has been appointed Deputy Director for Finance & Administration at Yale Cancer Center.

Novel Sintilimab Combo Significantly Improves PFS in EGFR-Mutated Nonsquamous NSCLC

October 18th 2021

Kristi Rosa

The combination of sintilimab, a bevacizumab biosimilar injection, and chemotherapy resulted in a significant improvement in progression-free survival in patients with EGFR-mutated, nonsquamous, non–small cell lung cancer that as progressed following treatment with an EGFR TKI, meeting the primary end point of the phase 3 ORIENT-31 trial.

Cemiplimab Earns High Marks in First-Line Treatment of Advanced NSCLC

October 18th 2021

Kyle Doherty

Ahmet Sezer, MD, discusses how the approval of cemiplimab could potentially make a huge impact for patients with advanced non–small cell lung cancer.

New Subcutaneous, Oral, and Intravenous Therapies Transform Treatment in Early-Stage HER2+ Breast Cancer

October 18th 2021

Jessica Hergert

Francisco Javier Esteva, MD, PhD, discussed the current approach to treating patients with early-stage HER2-positive breast cancer, unmet needs in the space, and future directions with neratinib and T-DM1.

See All News